|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||257.09 - 260.17|
|52 Week Range||176.11 - 294.57|
|Beta (3Y Monthly)||0.78|
|PE Ratio (TTM)||53.81|
|Earnings Date||Jan 30, 2020 - Feb 3, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||301.50|
Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.
The charts of IDEXX Laboratories and Zoetis have weakened recently, and while the Westminster Dog Show is not for a few more months, it looks like these stocks could be going to the dogs. In this daily bar chart of IDXX, below, we can see that prices traded sideways since June with buyers showing up around $260 until today.
Return on equity is one of the most popular ways for investors to assess the efficiency of a business before they buy a stock. Return on equity is a measure of profitability relative to shareholder’s equity. ...
Idexx (IDXX) delivered earnings and revenue surprises of 9.73% and 1.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
WESTBROOK, Maine , Oct. 31, 2019 /PRNewswire/ -- Reports revenue growth of 11% on a reported basis and 12% on an organic basis, driven by Companion Animal Group ("CAG") Diagnostics recurring ...
Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.
There are many ways for fundamental investors to gauge the profitability of a business, and one common method is looking at return on assets. Return on assets is simply a measure of profitability relative ...
Fido and Fluffy have health concerns, too, and animal health companies like Zoetis and Idexx Laboratories are in hot pursuit of the rapidly developing pet health market.
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WESTBROOK, Maine, Oct. 24, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced that Jonathan Ayers is stepping down as Chairman and a member of the IDEXX management team, effective November 1, 2019. This decision follows Mr. Ayers's previously announced medical leave of absence from IDEXX due to a bicycling accident, where he suffered a spinal cord injury.
Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]
WESTBROOK, Maine , Oct. 10, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled ...
This is the second of two stories that Investopedia is devoting to a report from Goldman Sachs recommending stocks with longterm stable profit growth.
WESTBROOK, Maine , Oct. 2, 2019 /CNW/ -- IDEXX Laboratories, Inc. (IDXX), a global leader in veterinary diagnostics and software, today announced that SDMA-based chronic kidney disease (CKD) staging guidelines have now been generated and approved by the International Renal Interest Society (IRIS). IDEXX is working with IRIS to support clinicians in realizing the clinical utility of the SDMA test and in creating tools that help shape the future of veterinary medicine and patient care.
For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality...
Shares of medical stocks Idexx Laboratories and Masimo approached breakouts Friday as Wall Street enjoyed a third day of gains. Both stocks are now in the process of forming flat bases.